What’s happening to the Novacyt share price?

The Novacyt share price surged 6,000% in 2020. But this year, the stock has plummeted. Zaven Boyrazian investigates what’s happened.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2020 was a game-changing year for Novacyt (LSE:NCYT) that saw its share price explode from 14p to over 850p. That’s a return of nearly 6,000% in the space of a year! But since the start of 2021, more than half of this gain has been wiped out. And last week, this downward trajectory continued. What’s causing this extreme volatility?

The rise and fall of the Novacyt share price

Novacyt is a medical diagnostics business. And before Covid-19 came into the picture, it was a relatively small company that developed and sold pathogen testing kits for the medical, life science, and food industries. The pandemic has caused chaos for many sectors. But for Novacyt, it presented an incredible opportunity.

Using its knowledge, the company developed and launched the first Covid-19 rapid testing kits months ahead of its competitors. With demand surging and the supply practically non-existent, Novacyt found itself in a mini-monopoly that triggered a 900% rise in revenue. Needless to say, this level of growth is extraordinary. So seeing the Novacyt share price surge by millionaire-making percentages in the space of a year is not that surprising. Alas, this explosive growth would not last.

Some 50% of the newly-found revenue stream came from a single contract signed with the UK Department of Health and Social Care (DHSC). Despite Novacyt delivering on all promised supply milestones, the DHSC decided not to extend the contract in early April this year. In other words, 50% of Novacyts expected revenue for 2021 just disappeared.

The management team is pursuing legal action against the DHSC to enforce its contract. But there is no guarantee that this will yield a different result. And so, the Novacyt share price has plummeted.

The Novacyt share price has a lot of risks

Moving Forward

Seeing a massive portion of its income disappear is a painful sight, especially when there haven’t been any announcements regarding how this lost revenue will be replaced. However, it was undoubtedly going to happen eventually. After all, once the pandemic is over, the need for these rapid testing kits will likely decline.

Developing and launching new medical products is an expensive endeavour. But thanks to its stellar performance last year, the firm’s cash balance now sits at £91.8m. Beyond providing a high level of liquidity, it can fund this necessary research and fuel any potential acquisitions. Providing these ventures bear fruit, the Novacyt share price could begin climbing again over the long term.

Closing thoughts

In my experience, investing in a company embroiled in a lawsuit is not a particularly sound strategy. But should Novacyt emerge victorious, the return of its lost revenue will undoubtedly send its share price surging once more.

Personally, I’m not interested in taking this risk. Court battles can be long, expensive and distracting for the management team who should be focused on running the business. It could be many months or even years before this matter is resolved. And by then, the need for rapid Covid-19 testing kits may no longer exist. Therefore I won’t be adding the shares to my portfolio today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Novacyt. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »